KDC-MN-398 – Kodiac biolabs

Plain-language summaryIntrigue 38 / 100

L-glutamine is the most abundant free amino acid in human plasma, serving as a fuel substrate for gut lining cells and immune cells and as an ammonia transport carrier. Clinical evidence is solid in critical illness contexts (severe burns, sepsis, post-surgical recovery), where parenteral or enteral glutamine improves nitrogen balance and may reduce infection rates. The popular supplement use in healthy athletes for recovery and immune support, however, has very thin supporting evidence: most oral glutamine is extracted by the gut on first pass and never reaches systemic circulation. Reference amino acid in immunometabolism and clinical nutrition research, but generally overhyped in the supplement context. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

28/100

Conditionally essential amino acid with solid critical-care history but minimal frontier research value

Look, glutamine is the most abundant free amino acid in human plasma, and that abundance tells you something important: this is basic cellular infrastructure, not frontier pharmacology. The compound has been characterized for decades. The biology is mature. The interesting questions about glutamine have largely been answered, and the field has moved on to more specific modulators of the pathways glutamine feeds into.

The mechanism is real and worth understanding. Enterocytes and immune cells run on glutamine during catabolic stress states, and in the ICU context, burns, sepsis, post-surgical recovery, parenteral and enteral glutamine supplementation has demonstrated genuine benefit. Nitrogen balance improvements and reduced infection rates have been replicated across multiple centers. Thats legitimate evidence, and we give it credit here. The problem is what happens when you move outside the critical care ward.

Oral supplementation in healthy or recreationally active individuals is a fundamentally different situation. The gut extracts the vast majority before it reaches systemic circulation. Plasma half-life is about an hour. Claims around athlete recovery, gut permeability, and immune support in healthy populations have not held up well under controlled conditions. The supplement market ran well ahead of the evidence and stayed there. We dont find this surprising given the pharmacokinetics.

As a research tool, glutamine has a narrow supporting role. It functions as a reference amino acid in immunometabolism work, useful for establishing nitrogen flux baselines, tracking amino acid transfer via metabolic tracers, and studying enterocyte energy dependence. But thats a background role in someone else’s experiment. The more interesting action in amino acid signaling right now sits with SLC1A5/ASCT2 modulators, glutaminase inhibitors in oncology (CB-839 and related compounds), and the intersection of glutamine sensing and mTOR complex activation. Those are the derivative questions worth pursuing; glutamine itself is the substrate, not the lever.

The one area we’d monitor is the critical-illness subpopulation question. There’s ongoing effort to define which patients actually benefit and at what illness stage, including revisiting the mixed results from the REDOX and SUGARMILL trials. That’s clinical nutrition work with real stakes. But it’s not exploratory pharmacology and it doesn’t change what glutamine is as a research object.

For the library, glutamine earns its place as reference context. It’s part of the vocabulary. It’s not an investigation target for a serious bench program right now.

Novelty: 10
Mechanism promise: 18
In-category differentiation: 18
Evidence quality: 52
Translational signal: 48
Research bench value: 38

Rationale Raw calculation lands at 28, already below the 32 basic-aa cap, so the cap does not further limit the score. Novelty and differentiation drag the total down hard; evidence gets partial credit for replicated critical-care trials, but bench value is narrow and translational signal evaporates outside the ICU context.

Conditionally essential amino acid (immunometabolic substrate)

L-glutamine; the most abundant free amino acid in plasma; a substrate for enterocyte and immune cell metabolism and a popular but evidence-limited supplement.

Abstract

L-glutamine ((S)-2,5-diamino-5-oxopentanoic acid; CAS 56-85-9; molecular formula C5H10N2O3; molecular weight 146.14) is a conditionally essential alpha-amino acid that is the most abundant free amino acid in human plasma (approximately 500 to 800 micromolar). Glutamine is biosynthesized from glutamate and ammonia by glutamine synthetase, with skeletal muscle and lung as principal source tissues. The compound serves as a substrate for enterocyte and immune cell metabolism (the principal biological role outside protein synthesis) and as an ammonia transport carrier. Clinical use is well-established in critical illness (burn injury, sepsis, post-surgery) where parenteral or enteral glutamine improves nitrogen balance and may reduce infection rates; the supplement use in healthy athletes for recovery and immune support has limited supporting evidence. Plasma half-life is approximately 1 hour; the gut largely extracts oral glutamine, with minimal systemic delivery. Used as a reference amino acid in immunometabolism and clinical nutrition research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-398Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-398

L-Glutamine

Abstract

Read the full monograph